ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,321.41
      0.25%
      US Tech 100
      18,232.00
      0.00%
      Dow Jones
      39,872.99
      0.17%
      Brent Oil
      81.68
      -0.93%
      Bitcoin
      69,733.29
      -0.57%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. CytomX Therapeutics Inc (CTMX)

      7. CytomX Therapeutics Inc (CTMX) News

      CTMX

      CytomX Therapeutics (CTMX)

      CytomX Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CTMX
      DateTimeSourceHeadlineSymbolCompany
      05/17/20245:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      05/17/20245:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      05/17/20245:34PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      05/17/20245:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      05/17/20245:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      05/17/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
      05/16/20244:15PMGlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
      05/13/20244:00PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CTMXCytomX Therapeutics Inc
      05/08/20244:41PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
      05/08/20244:10PMGlobeNewswire Inc.CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)NASDAQ:CTMXCytomX Therapeutics Inc
      05/08/20244:10PMGlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
      05/08/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
      05/08/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
      05/07/20244:15PMGlobeNewswire Inc.CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:CTMXCytomX Therapeutics Inc
      05/01/20248:00AMGlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
      04/08/20248:00AMGlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
      04/03/20248:00AMGlobeNewswire Inc.CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
      03/21/20248:00AMGlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
      03/18/20248:00AMGlobeNewswire Inc.CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
      03/11/20244:30PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTMXCytomX Therapeutics Inc
      03/11/20244:10PMGlobeNewswire Inc.CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
      03/11/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
      03/11/20244:00PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTMXCytomX Therapeutics Inc
      03/11/20246:39AMIH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:CTMXCytomX Therapeutics Inc
      03/04/20248:00AMGlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024NASDAQ:CTMXCytomX Therapeutics Inc
      02/27/20248:00AMGlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
      01/24/20248:00AMGlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
      01/19/20248:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      01/19/20248:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
      01/19/20248:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CTMX